The Role of Biotechnology in Medicine

Biotechnology harnesses living organisms—bacteria, yeast, fungi, plant cells, and mammalian cell lines—to produce high-value medicinal compounds that are otherwise scarce, expensive, or environmentally damaging to extract. This discipline bridges biology, chemistry, and engineering, enabling the synthesis of complex molecules with high purity and consistency. The advantages over traditional extraction or total chemical synthesis are substantial: lower energy consumption, reduced use of toxic solvents, minimized ecological footprint, and the ability to produce compounds that are structurally too complex for cost-effective chemical synthesis. Today, biotechnological methods underpin the manufacture of hundreds of approved drugs and are the only viable pathway for many rare or structurally intricate natural products.

Modern bioprocessing platforms are designed for scalability, from milligram-scale laboratory fermentations to thousands-of-liters industrial bioreactors. This scalability is critical for rare medicinal compounds, where even small improvements in yield can dramatically lower costs and increase patient access. Biotechnology also enables the production of analogues and derivatives that enhance efficacy, reduce toxicity, or improve pharmacokinetics—an approach that has been successfully applied to antibiotics, anticancer agents, and immunosuppressants.

Genetic Engineering and Synthetic Biology

Genetic engineering allows researchers to introduce, delete, or modify genes within microorganisms to create cellular factories that produce target compounds. Using recombinant DNA technology, scientists can transfer the biosynthetic pathway of a rare plant metabolite—often consisting of multiple enzymes—into a fast-growing host such as Escherichia coli or Saccharomyces cerevisiae. For example, the entire biosynthetic pathway for the opioid painkiller hydrocodone has been expressed in yeast, paving the way for a fermentation-based production system that bypasses the cultivation of opium poppies.

Synthetic biology extends this concept by designing and assembling novel genetic circuits from standardized parts. It enables the optimization of metabolic flux, the elimination of bottlenecks, and the creation of entirely new-to-nature pathways. Tools such as CRISPR-Cas9 gene editing allow precise modifications to host genomes, improving yields and reducing byproduct formation. Synthetic biology has also been used to produce rare natural products like artemisinin, taxol precursors, and cannabinoids, demonstrating its power to unlock compounds previously limited by natural supply constraints. Researchers at the University of California, Berkeley, for instance, engineered yeast to produce artemisinic acid—a direct precursor to the antimalarial drug artemisinin—at yields competitive with traditional extraction from Artemisia annua plants.

Fermentation and Bioreactor Technologies

Fermentation is the controlled cultivation of microorganisms in bioreactors to produce target metabolites. Advances in fermentation technology include fed-batch and continuous processes, real-time monitoring of pH, oxygen, and nutrient levels, and the use of advanced sensors and control algorithms. These improvements have dramatically increased cell density and product titers. For example, the production of recombinant human insulin—one of the earliest biotech success stories—relies on high-density fermentation of E. coli or yeast, yielding pure insulin at a fraction of the cost of extraction from animal pancreases.

Beyond traditional submerged fermentation, new formats such as biofilm reactors, membrane bioreactors, and single-use disposable bioreactors are gaining traction. Single-use bioreactors reduce contamination risks and clean-up costs, making them ideal for producing rare compounds in flexible, multi-product facilities. Additionally, bioprocess intensification strategies—such as cell immobilization, in situ product removal, and perfusion culture—can further boost productivity and simplify downstream processing. For rare medicinal compounds, these innovations are essential to achieve economically viable production at commercial scale.

Plant Cell and Tissue Culture

When a compound is too complex for microbial synthesis, plant cell culture offers a powerful alternative. This technique involves growing dedifferentiated plant cells (callus) or organized tissues (hairy roots, shoots) in sterile liquid media. By manipulating growth regulators, nutrient composition, and elicitors (e.g., jasmonic acid, chitosan), researchers can induce the accumulation of secondary metabolites that are normally produced only in specific plant organs or under stress. Plant cell cultures have been successfully commercialized for the production of paclitaxel (Taxol), shikonin, and ginsenosides.

Bioreactor design for plant cells presents unique challenges due to shear sensitivity, slow growth, and tendency to aggregate. However, innovations in low-shear impellers, airlift bioreactors, and transient expression systems (e.g., using Agrobacterium or viral vectors) have expanded the toolkit. For instance, the production of the anticancer compound podophyllotoxin has been achieved in cell cultures of Podophyllum hexandrum, reducing the pressure on wild populations of this endangered plant. Similarly, the production of the anticholinergic agent scopolamine in transformed hairy root cultures of Hyoscyamus muticus offers a scalable and sustainable alternative to field cultivation.

Enzyme Engineering and Biocatalysis

Purified enzymes or whole-cell biocatalysts can perform highly selective chemical transformations that are difficult or impossible with traditional synthetic methods. Enzyme engineering—through directed evolution or rational design—allows optimization of activity, stability, and substrate specificity. This approach is particularly valuable for producing rare compounds that require regio- or stereoselective hydroxylations, glycosylations, or methylations. For example, the FDA-approved drug islatravir, an HIV reverse transcriptase inhibitor, is manufactured using an engineered enzyme cascade that achieves high yield and purity in a single biocatalytic step.

Biocatalysis also enables the derivatization of rare natural products to improve their pharmacological properties. Glycosyltransferases can attach sugar moieties to improve solubility; cytochrome P450s can introduce hydroxyl groups to enhance activity. In many cases, enzyme cascades can replace multi-step chemical syntheses, reducing waste and energy consumption while increasing overall efficiency.

Key Innovations in Producing Rare Medicinal Compounds

The application of these biotechnological platforms has led to several landmark achievements in the production of rare medicinal compounds. Below are illustrative examples that highlight the diversity and impact of these innovations.

Artemisinin: From Plant to Fermentation

Artemisinin is a potent antimalarial compound derived from the sweet wormwood plant (Artemisia annua). Traditional extraction is limited by low yields (0.01–0.8% of dry weight), seasonal supply, and high cost, making it unaffordable for many patients in endemic regions. In a pioneering effort, researchers at the University of California, Berkeley, and the company Amyris engineered Saccharomyces cerevisiae to produce artemisinic acid, a direct precursor that can be converted to artemisinin via a simple chemical step. The yeast strain was optimized through synthetic biology to express a plant-derived amorphadiene synthase, a cytochrome P450, and a reductase, along with improved flux through the mevalonate pathway. Fermentation titers now exceed 25 g/L of artemisinic acid, and the process has been scaled to commercial production by Sanofi. This biotechnological breakthrough has stabilized global supply and reduced the price of artemisinin-based combination therapies. Today, approximately one-third of the global artemisinin supply is produced via fermentation, a share that continues to grow.

Further advances include the development of semi-synthetic artemisinin derivatives with improved pharmacokinetics, such as artemether and artesunate, which can also be produced using engineered microbial strains. Research is ongoing to engineer a complete biosynthesis of artemisinin itself, bypassing the chemical conversion step entirely.

Insulin: The Original Recombinant Success

Before the advent of recombinant DNA technology, insulin for diabetes management was extracted from the pancreases of pigs and cows. This approach was expensive, limited in supply, and carried risks of allergic reactions due to species differences. In 1978, Genentech became the first company to produce human insulin in E. coli by expressing the insulin A and B chains separately and then chemically combining them. Later, improved strains allowed the expression of proinsulin, which is enzymatically cleaved to yield active human insulin. Today, yeast-based systems (e.g., Saccharomyces cerevisiae) are widely used to produce recombinant insulin and insulin analogues (e.g., lispro, glargine) with altered absorption profiles. Large-scale fermentation yields tens of grams per liter of proinsulin, and downstream purification yields >99% pure product. This biotechnological innovation has made insulin affordable and universally available, saving millions of lives worldwide.

Recent developments include the production of oral insulin formulations using encapsulation technologies and the engineering of “smart” insulin analogues that release glucose in response to blood sugar levels. While these are still in clinical development, they underscore the continued evolution of biotechnological approaches to rare compound production.

Paclitaxel (Taxol): Plant Cell Culture at Scale

Paclitaxel is a diterpenoid anticancer drug originally isolated from the bark of the Pacific yew tree (Taxus brevifolia). Harvesting the bark kills the tree, and supply could never meet clinical demand—only a few hundred grams could be obtained per year. Total chemical synthesis is impractical due to the molecule’s 11 stereogenic centers. The solution came from plant cell culture technology. In the 1990s, Bristol-Myers Squibb, in collaboration with a German company, developed a large-scale process using Taxus cell suspensions grown in 75,000-liter bioreactors. By optimizing medium composition, adding elicitors (e.g., methyl jasmonate, fungal extracts), and selecting high-producing cell lines, they achieved yields exceeding 1 g/L. This process now supplies most of the world’s paclitaxel. The same platform has been extended to produce other taxanes, including docetaxel and cabazitaxel.

More recently, heterologous production of paclitaxel precursors in yeast has been reported, though the full pathway (including oxygenation and acylation steps) remains challenging. Combining plant cell culture with metabolic engineering and synthetic biology promises even higher yields and the ability to produce novel taxoids with improved anticancer activity.

Cannabinoids and Opioids: Fermenting Controlled Substances

The production of cannabinoids (e.g., THC, CBD) and opioids (e.g., morphine, codeine) via fermentation offers a way to produce these compounds under controlled, sterile conditions, independent of plant cultivation and extraction. Both classes contain complex stereochemistry and are subject to regulatory constraints that limit field cultivation. Using engineered yeast, researchers at the University of California, Berkeley, and the University of Copenhagen have successfully produced Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) by expressing the multi-step cannabinoid pathway from Cannabis sativa. Key innovations included engineering a yeast strain that produces high levels of olivetolic acid and geranyl diphosphate, which are then condensed by a prenyltransferase and cyclized to form cannabigerolic acid. Further enzymatic steps yield THC or CBD. Titers are currently in the milligram-per-liter range, but ongoing metabolic engineering aims to increase yields to commercial levels.

Similarly, the complete biosynthesis of the opioid hydrocodone from sugar in yeast has been demonstrated. This 21-step pathway involves enzymes from plants, mammals, and bacteria, and produces thebaine as an intermediate—a controlled precursor. While challenges remain in yield optimization and regulatory compliance, these proof-of-concept studies highlight the potential to produce rare, high-value medicinal compounds via fermentation in a safe, scalable manner.

Resveratrol and Flavonoids: Biotech for Nutraceuticals

Resveratrol, a polyphenolic compound found in red wine and grapes, has garnered interest for its potential cardioprotective and anti-aging effects. However, its low natural abundance (0.1–10 mg/g in grape skins) and poor bioavailability limit dietary intake. Recombinant production in Saccharomyces cerevisiae and Escherichia coli has been achieved by expressing the plant phenylpropanoid pathway, including phenylalanine ammonia lyase (PAL), cinnamate 4-hydroxylase (C4H), and resveratrol synthase (STS). Yields exceeding 400 mg/L have been reported, with further improvements through protein engineering and pathway balancing. This biotechnological route allows the production of high-purity resveratrol at low cost for nutraceutical and cosmetic applications. The same platform can be adapted for other flavonoids, such as quercetin, kaempferol, and catechins, by introducing appropriate modifying enzymes. These compounds have demonstrated antiviral, anti-inflammatory, and anticancer activities, making them targets for pharmaceutical development.

Overcoming Challenges in Bioproduction

Despite the successes, the biotechnological production of rare medicinal compounds faces several significant challenges. Addressing these is crucial for broadening the pipeline of drugs that can be produced sustainably.

Pathway Complexity and Uncharacterized Enzymes

Many rare natural products are synthesized in plants through long, branched pathways involving dozens of enzymes, some of which are membrane-bound, require cofactors, or are regulated by compartmentalization. Identifying and cloning all necessary genes from non-model plants is often the first major hurdle. Advances in genomics, transcriptomics, and metabolomics have accelerated enzyme discovery, but many steps remain unknown. For example, the full biosynthetic pathway for vinblastine, a potent anticancer alkaloid from Catharanthus roseus, was only fully elucidated in 2018—after decades of research. Synthetic biology can help by reconstructing pathways in modular fashion and testing candidate enzymes in parallel.

Furthermore, enzymes from plants often do not function well in microbial hosts due to differences in pH, temperature, redox environment, or post-translational modifications. Directed evolution and protein engineering are used to adapt these enzymes for microbial expression, but this remains a labor-intensive process. Machine learning-based prediction tools are emerging to design optimized enzymes, potentially reducing development timelines from years to months.

Yield and Titer Optimization

Even with a functional pathway, yields may be too low for commercial viability. Microbial metabolism is inherently balanced, and diverting large carbon fluxes toward a heterologous product can lead to growth inhibition, accumulation of toxic intermediates, or metabolic burden. Common optimization strategies include: (1) knockout of competing endogenous pathways, (2) over-expression of rate-limiting enzymes, (3) engineering of cofactor regeneration (e.g., NADPH supply for cytochrome P450s), (4) use of strong inducible promoters, and (5) dynamic control of pathway expression via biosensors. In some cases, genome-wide CRISPR screens identify genes whose disruption improves production. For example, in yeast engineered for artemisinic acid, deletion of the gene encoding squalene synthase (which diverts flux toward sterols) doubled titers. Similarly, for opioid production, disruption of competing branch points improved yields several fold.

Process optimization also plays a role: feeding strategies, oxygen transfer, and pH control can make a 10-fold difference in final titer. High-throughput screening in microtiter plates, followed by scaled-up validation in bioreactors, is the standard workflow. Despite these tools, commercial production of rare compounds often requires years of iterative strain and process development.

Downstream Processing and Purification

The compound of interest is typically present in a complex mixture of cellular components, secreted metabolites, and media components. Achieving the high purity (>99%) required for pharmaceutical use demands multiple separation steps: centrifugation or filtration for cell removal, extraction (liquid-liquid or solid-phase), precipitation, chromatography (ion exchange, hydrophobic interaction, size exclusion), and often crystallization. For compounds that are unstable, light-sensitive, or prone to degradation, these steps must be performed under inert atmospheres or at low temperatures, increasing costs.

Innovations in downstream processing, such as aqueous two-phase systems, membrane-based purification, and continuous chromatography, can reduce solvent use and increase throughput. In situ product removal (ISPR) during fermentation—using a second phase (e.g., an organic solvent or a resin) that selectively adsorbs the product—can reduce toxicity and increase yield while simplifying downstream recovery. For example, the production of the antibiotic erythromycin uses a non-ionic resin that binds the product during fermentation, leading to a 5-fold increase in productivity.

Regulatory and Economic Hurdles

Bringing a biotechnologically produced rare compound to market requires regulatory approval from agencies like the FDA or EMA. The process must demonstrate that the recombinant product is equivalent in structure, purity, and activity to the natural compound, and that the manufacturing process is consistent and controlled. For compounds that are also natural products, it may be necessary to prove that the impurity profile does not introduce new safety concerns. Additionally, if the compound is a controlled substance (e.g., opioids), additional regulations apply for handling, transport, and record-keeping.

Economically, the cost of developing a bioproduction process is high—often tens to hundreds of millions of dollars—and the market for rare compounds may be small (e.g., orphan drugs for rare diseases). Business models must balance high development costs against potential revenue. Public-private partnerships, as seen with artemisinin (funded by the Gates Foundation and the WHO), can reduce financial risk. For broader market compounds, such as insulin, the fixed costs of fermentation facilities are amortized over large volumes, making them economically viable.

Future Directions

Ongoing research and technological convergence are poised to dramatically expand the scope and efficiency of biotechnological production of rare medicinal compounds.

CRISPR-Based Genome Engineering

CRISPR-Cas9 and its derivatives (e.g., base editors, prime editors, CRISPRi/a) enable precise, multiplexed modifications to host genomes. These tools allow researchers to rapidly test thousands of genetic variants to identify optimal configurations for high production. For example, CRISPRi (interference) can be used to knock down expression of endogenous genes that divert flux away from the target pathway, without needing to create complete knockouts that may impair growth. Whole-cell models combined with CRISPR screens can predict and validate the best targets. In the coming decade, we can expect the construction of “minimal genomes” for industrial hosts—strains stripped of unnecessary genes to maximize metabolic efficiency for compound production.

Artificial Intelligence and Machine Learning

Machine learning algorithms are being applied to predict enzyme function, metabolic flux, and optimal culture conditions. For example, the software platform “BiosensorML” can design genetic circuits that control pathway expression in real-time based on metabolite concentrations. AI also assists in retrosynthetic planning: given a target molecule, the algorithm suggests the most efficient biotechnological route, drawing on a database of known enzymes and reactions. This capability is especially valuable for rare compounds with no previously known biosynthetic pathway. Startups like Zymergen and Ginkgo Bioworks use machine learning to optimize strains faster than traditional trial-and-error methods.

Cell-Free Synthetic Biology

Cell-free systems circumvent the growth and toxicity limitations of living cells by using purified enzymes or crude cell extracts in controlled reaction mixtures. Initial applications focused on biosensors and diagnostic devices, but recent work has demonstrated the scalable production of several complex compounds, including cannabinoids and HIV reverse transcriptase inhibitors. Cell-free systems offer advantages: faster iteration, tolerance to toxic products, and ability to use non-natural substrates. A landmark study published in Nature Communications in 2019 showed production of the antibiotic neomycin in a cell-free extract at gram-scale. As costs come down, cell-free production could become a viable option for rare compounds that are difficult to produce in whole-cell platforms.

Nanotechnology-Enhanced Bioprocessing

Nanomaterials such as carbon nanotubes, gold nanoparticles, and magnetic beads are being used to immobilize enzymes or capture products during fermentation. Enzyme immobilization on nanostructures can enhance stability and allow easy recovery and reuse, drastically reducing costs. Nanoscale biosensors can monitor product and metabolite levels in real time, enabling precise control of fermentation parameters. In downstream processing, nanoparticles functionalized with specific binding moieties (e.g., antibodies, aptamers) can selectively capture the target compound from a complex broth in a single step, replacing multiple chromatography columns. For example, magnetic nanoparticles coated with a monoclonal antibody against the anticancer compound docetaxel have been used to achieve >95% purity in one pass.

Personalized and On-Demand Production

One long-term vision is the ability to produce rare medicinal compounds on-demand, in small volumes, at the point of care. Miniaturized bioreactors and synthetic biology platforms could be integrated into pharmacy systems, allowing clinicians to prescribe patient-specific compounds that are not commercially available. For example, a child with a rare metabolic disorder might receive a customized enzyme replacement therapy produced by engineered yeast at a local fermentation facility. While still far from reality, early proof-of-concept work has shown that small-scale, rapid manufacturing of monoclonal antibodies is feasible using portable bioreactors. Such developments would be transformative for rare diseases, where existing treatments are often exorbitantly expensive or unavailable.

Conclusion

Biotechnological innovations have fundamentally changed how we produce rare medicinal compounds, moving from extraction from limited natural sources to engineered fermentation, plant cell culture, and biocatalysis. These methods offer sustainability, scalability, and purity while enabling the creation of analogues and derivatives with improved properties. Landmark achievements—artemisinin from yeast, insulin from E. coli, paclitaxel from plant cells—demonstrate the power and viability of this approach. As tools like CRISPR, artificial intelligence, cell-free systems, and nanotechnology continue to mature, the pipeline of rare compounds accessible through biotechnology will only expand. The ultimate beneficiaries are patients who will gain access to life-saving medications that were previously too rare, too expensive, or simply unavailable. By investing in these technologies, we are building a future where the bottleneck for drug development is no longer the scarcity of nature, but the creativity of human ingenuity.